Acquired Immunodeficiency Syndrome Clinical Trial
Official title:
Accuracy Evaluation of the BD FACS Presto System: Instrument, Software and BD CD4/%CD4/Hb Cartridge Assay
The enumeration of T lymphocytes positive for the CD4 antigen is used to determine the
immune status of patients with, or suspected of developing, immune deficiencies such as
AIDS. The BD FACS Presto™ is an investigational automated system for in vitro diagnostic use
in performing the direct enumeration of CD4 absolute count, CD4 percentage of lymphocytes,
and hemoglobin (Hb) concentration in human whole blood.
This is a prospective study to determine the relative bias between the investigational BD
FACS Presto system and the predicate BD FACS Calibur with BD Tritest system in their
determination of absolute CD4, % CD4, and Hb concentrations.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01968551 -
Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults
|
Phase 3 | |
| Completed |
NCT02929069 -
A Unified Intervention for Young Gay and Bisexual Men's Minority Stress, Mental Health, and HIV Risk
|
N/A | |
| Recruiting |
NCT02392884 -
HIV Medication Adherence in Underserved Populations
|
N/A | |
| Completed |
NCT02583464 -
Bioequivalence Study of Two Formulations With the Association of Tenofovir 300 mg and Emtricitabine 200 mg.
|
Phase 1 | |
| Completed |
NCT02264509 -
Peripheral Arterial Insufficiency Associated With HIV/AIDS
|
N/A | |
| Completed |
NCT01440569 -
Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
|
Phase 3 | |
| Completed |
NCT00551330 -
Vicriviroc in HIV(R5/X4)-Treatment Experienced Subjects (Study P05057AM5)(COMPLETED)
|
Phase 2 | |
| Completed |
NCT00381212 -
A Pilot Study to Investigate the Safety and Immunologic Activity AGS-004 an Autologous HIV Immunotherapeutic Agent.
|
Phase 1/Phase 2 | |
| Completed |
NCT00097006 -
Retrovirus Epidemiology Donor Study-II (REDS-II)
|
N/A | |
| Completed |
NCT00001409 -
Genetically Modified Lymphocytes to Treat HIV-Infected Identical Twins - Study Modifications
|
Phase 1 | |
| Completed |
NCT00000590 -
Anti-HIV Immunoglobulin (HIVIG) in Prevention of Maternal-Fetal HIV Transmission (Pediatric ACTG Protocol 185)
|
Phase 3 | |
| Completed |
NCT00000587 -
Erythropoietin for Anemia Due to Zidovudine in Human Immunodeficiency Virus Infection
|
Phase 2 | |
| Completed |
NCT00005273 -
Pulmonary Complications of HIV Infection Study (PACS)
|
N/A | |
| Completed |
NCT00005303 -
Effectiveness of AIDS Antibody Screening
|
N/A | |
| Completed |
NCT00005301 -
Transfusion Safety Study (TSS)
|
N/A | |
| Completed |
NCT00001650 -
Use of Bromodeoxyuridine to Study White Blood Cell Replication and Survival in HIV-Infected Patients
|
N/A | |
| Withdrawn |
NCT00243568 -
Vicriviroc, a CCR5 Inhibitor, Added to an Optimized Antiretroviral Therapy for Previously Treated HIV (VICTOR-E2) (Study P04285
|
Phase 3 | |
| Recruiting |
NCT05031819 -
Managing Hypertension Among People Living With HIV
|
N/A | |
| Completed |
NCT00394004 -
Decision-Making of Hispanics and African-Americans With HIV/AIDS Participating in Clinical Trials
|
N/A | |
| Completed |
NCT01967940 -
Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults
|
Phase 3 |